Servier

News

ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t

News

Servier doubles up on ‘digital twin’ alliance with Aitia

French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and

News

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

News

ASCO-GI data sets up wider use of Ipsen's Onivyde

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023

News

Rebranded Servier eyes €3bn in cancer drug sales by 2030

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category.

News

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Ipsen and Servier's hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cance

ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier doubles up on ‘digital twin’ alliance with Aitia

Servier’s $1.8bn Agios deal delivers glioma prospect

ASCO-GI data sets up wider use of Ipsen's Onivyde

Rebranded Servier eyes €3bn in cancer drug sales by 2030

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

Servier

Editor's Picks